Drugs / ASP2713
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04017208 | Jul 2019 → Aug 2020 | — | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2713 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04017208 ↗ |
| Route | Intravenous | “Administered intravenously” NCT04017208 ↗ |